Bevacizumab

Min.Order / FOB Price:Get Latest Price

0 Metric Ton	Negotiable

0 Metric Ton

Negotiable

Min.Order :0 Metric Ton
Purity: >99.0%
Payment Terms : T/T

Keywords

Bevacizumab Anti-Human VEGF Humanized Antibody

Quick Details

Appearance:Colorless to light yellow (Liquid)
Application:Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
PackAge:1mg, 5mg
ProductionCapacity:|Metric Ton|Day
Storage:Store at 4°C,Do not freeze
Transportation:By Air

Superiority:

Product Name: Bevacizumab

Appearance: Colorless to light yellow (Liquid)

Purity (CE-SDS): >99.0%

Concentration: 25 mg/ml

pH Value: 6.1

Endotoxin Level: <2 EU/ml

Sterility Test: PASS

Activity: 1E4 U/mg

Details:

Biological Activity:

In Vitro: Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2. Experimental analysis shows that the EC₅₀ of Bevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC₅₀ value of 0.047±0.0081 μg/mL.

In Vivo: It is demonstrated that the subconjunctival administration of FD006, Bevacizumab and Dexamethasone can all significantly inhibit CoNV in NaOH cauterized rats compared with the control group (p < 0.01). The combination of NVP-LDE225 and Paclitaxel causes a long-lasting antitumor activity, with a tumor size of 1.64 cm³ at the end of the experiment, whereas Bevacizumab plus Paclitaxel-treated mice reaches the maximum allowed tumor size on day 84.

View All